You are here

An intravaginal ring for real-time evaluation of adherence to topical vagina

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI104549-01
Agency Tracking Number: R41AI104549
Amount: $211,862.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1512 11th Street
SANTA MONICA, CA -
United States
DUNS: 148679884
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN MOSS
 (626) 817-0883
 j.moss@oak-crest.org
Business Contact
 KIRSTEN TORGUSON
Phone: (626) 780-5317
Email: ktorguson@auritecpharma.com
Research Institution
 OAK CREST INSTITUTE OF SCIENCE
 
OAK CREST INSTITUTE OF SCIENCE 2275 E FOOTHILL BLVD
PASADENA, CA 91107-3658
United States

 () -
 Domestic nonprofit research organization
Abstract

DESCRIPTION (provided by applicant): The broad long-term of this project is to develop methods for evaluation of adherence to intravaginal microbicide therapy for the prevention of HIV transmission. Correct determination of adherence to preventative therapies in clinical trials is essential to accurate evaluation of efficacy. A better understanding of the true adherence to a preventative therapy will lead to the development of products with higher acceptability, and provide insight into the relationship between self-reported use of preventative therapy and actual use. Current methods of adherence evaluation for vaginal microbicide trials include self-reporting by study participants, physician or health care provider assessment, and inspection of study materials (gel applicators or used intravaginal rings) returned during clinic visits. All of these methods are prone to inaccuracy as indicated by the over-reporting of adherence observed in several clinical trials when adherence metrics were compared to trial outcomes. The proposed adherence-monitoring intravaginal ring (adherence IVR) will allow the direct measurement of adherence to IVR-delivered microbicide therapy by monitoring IVR temperature, conductivity, or both continuously on a half-hourly to hourly timescale to determine if the IVR is being worn or not during a clinical trial. The adherence IVR will contain a miniaturized module for sensing temperature (IVR at body temperature when in and below when out) and conductivity (IVR wetted and conductivity high when in, IVR dry and conductivity low when out) to determine adherence state. A microcontroller circuit embedded completely in the silicone ring structure will process the sensor data and store a digital adherence state (1 = IVR in, 0 = IVR out) to non-volatile memory at a fixed time interval. When the ring is removed, typically monthly, the adherence data may be downloaded from the IVR to a laptop computer or other device (smart phone or tablet) to provide a record of adherence that is free from reporting bias. The project has three principal objectives: (1) development of the microcontroller and sensor electronics and embedded software for sensor signal processing, conversion to digital adherence values, and logging to non-volatile memory for subsequentretrieval; (2) incorporation of this adherence monitoring functionality into a pod-IVR for intravaginal delivery of the microbicide tenofovir; and (3) evaluation of adherence monitoring performance, preliminary safety, and pharmacokinetics of tenofovir delivery in a sheep model. At the conclusion of this Phase I effort, a novel method for evaluating adherence to IVR microbicide therapy for prevention of HIV transmission will have been designed, fabricated, and evaluated in an animal model. The adherence-monitoring technology developed here may be extended to other pod-IVR delivery devices (i.e. microbicide combinations) and other IVR platforms. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This project aims to develop a novel method for assessing adherence to intravaginal ring (IVR)-based microbicide therapy for the prevention of HIV transmission in clinical trial settings. The proposed adherence IVR will utilize measurement of temperatore, conductivity, or both in combination to determine if the ring is being worn or not, and to log a continuous, digital record of adherence determination for subsequent retrieval at the study conclusion.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government